mGluR2/3 agonist for schizophrenia

[tr]

---

Members don't see this ad.

So I guess this came out in September (was there a thread about it then? if so I missed it), but anyway I found it in the paper today.

Looks as if the LY2140023 lags Zyprexa in efficacy only slightly, with no metabolic side effects. (Who knows what other problems it may cause of course.)

http://www.nature.com/nm/journal/v13/n9/abs/nm1632.html

http://www.nytimes.com/2008/02/24/business/24drug.html

The article in the paper says the new drug improves cognition as well - wouldn't that be a breakthrough - but there's nothing about that in the fulltext that I can see. Anybody know any more about this aspect of it?

 

[strangeglove]

I foresee combination therapy with atypicals.

 

[pseudoknot]

There was an interesting article on this in the NYTimes. Not so technical and maybe a little too starry-eyed, but interesting and brief.

http://www.nytimes.com/2008/02/24/business/24drug.html